NCT03840772 (ERASING) is a Phase 2 clinical trial of Eribulin in Solitary Fibrous Tumor, sponsored by Italian Sarcoma Group.

Who is sponsoring NCT03840772?

NCT03840772 is sponsored by Italian Sarcoma Group.

What drugs are being tested in NCT03840772?

Interventions in NCT03840772: Eribulin.

What condition does NCT03840772 study?

NCT03840772 studies Solitary Fibrous Tumor.

Is NCT03840772 still recruiting?

NCT03840772 is currently completed. Last updated 20 September 2024.

Last reviewed 2024-09-20 · How we verify

NCT03840772: ERASING

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eribulin in Advanced Solitary Fibrous Tumor

Completed Phase 2 Last updated 20 September 2024

What this trial tests

Phase 2 trial testing Eribulin in Solitary Fibrous Tumor in 16 participants. Completed in 18 September 2024.

Timeline

17 July 2019

Primary endpoint
18 September 2024

18 September 2024

Quick facts

Lead sponsor	Italian Sarcoma Group
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	17 July 2019
Primary completion	18 September 2024
Estimated completion	18 September 2024
Sites	3 locations across Italy

Drugs / interventions tested

Eribulin (ERIBULIN) — full drug profile →

Conditions studied

Solitary Fibrous Tumor — all drugs for Solitary Fibrous Tumor →

Sponsor

Italian Sarcoma Group — full company profile →

Who can join

18 and older, any sex, with Solitary Fibrous Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase II study on advanced Solitary Fibrous Tumor (SFT) treated with eribulin

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond.
de Bernardi A, Dufresne A, Mishellany F, Blay JY, et al · · 2022 · cited 48× · PMID 35205812 · DOI 10.3390/cancers14041064
Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors.
Janik AM, Terlecka A, Spałek MJ, Boye K, et al · · 2023 · cited 9× · PMID 38136399 · DOI 10.3390/cancers15245854
Potential role of marine species-derived bioactive agents in the management of SARS-CoV-2 infection.
Asif M, Saleem M, Yaseen HS, Yehya AH, et al · · 2021 · cited 5× · PMID 34689597 · DOI 10.2217/fmb-2021-0024
Systemic Therapy for Solitary Fibrous Tumor.
Stergiopoulos GM, Tinoco G, Robinson SI. · · 2026 · PMID 42149317 · DOI 10.1007/s11864-026-01383-3
Solitary fibrous tumour: histological discoveries, behavioural aspects, risk assessment and therapeutical approaches.
Di Prata C, Del Fiore P, Trevisiol C, Tropea S, et al · · 2025 · PMID 41164203 · DOI 10.1177/17588359251367320

Verify or expand the search:

Other trials of Eribulin

Trials testing the same drug.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT06957431 — Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma · Phase 1 · recruiting
NCT06942234 — Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06102824 — Organoid-based Functional Precision Therapy for Advanced Breast Cancer · Phase 2 · recruiting

Other recruiting trials for Solitary Fibrous Tumor

Currently open trials in the same condition.

NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Italian Sarcoma Group trials

Trials by the same sponsor.

NCT07265661 — Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma · NA · not yet recruiting
NCT07328425 — Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS · Phase 2 · recruiting
NCT06375941 — Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars · recruiting
NCT04274023 — Study on TSR-042 in Advanced Clear Cell Sarcoma · Phase 2 · terminated
NCT04383119 — Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03840772 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Italian Sarcoma Group
Last refreshed: 20 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03840772.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing